Skip to main content

Originally published Friday, November 2, 2012 at 1:45 PM

  • Share:
  • Comments (0)
  • Print

Seattle Genetics’ chief medical officer resigning

Seattle area’s most valuable biotech says Thomas Reynolds is stepping down at year-end.

Seattle Times staff

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >


Seattle Genetics, the region’s biggest biotechnology company by market capitalization, said chief medical officer Thomas Reynolds is resigning effective Dec. 31 “in connection with his retirement for a family health matter.”

Reynolds, who turned 53 in March, joined the company in 2007 and led its clinical and regulatory teams during the development and approval of its cancer drug Adcetris.

The company said it has started the search for his replacement.

Its stock price closed Friday at $24.33 a share, down 4 percent.

News where, when and how you want it

Email Icon

Relive the magic

Relive the magic

Shop for unique souvenirs highlighting great sports moments in Seattle history.



NDN Video